Aicube Presentation Pitch

1. THE AICUBE PROJECT
Stefano Russano | Founder & CEO @TheAICube | stefano.russano@theaicube.com

2. THE
PROJECT
The AICube company has been founded to provide
alternative solutions to different stakeholders in Health
Prevention and Predictive Medicine. Move healthcare
investment to prevention is mandatory to reduce the
unsustainable cost increase of the healthcare system.
Leverage on innovative approach through Machine
Learning technology is our main focus.

3. PROBLEM SUMMARY
Global Healthcare spend projected to growth up to $8.7 Trillion by 2020 from $7 in 2015.
Higher spending levels don’t always produce better health outcomes and value.
Population health requires data and analytics to identify at-risk patients and target services that reduce
their use of expensive and low-quality care.
Prevalence of dementia is
forecast to increase in every
region of the world and is
anticipated to double every 20
years, reaching 74.7 million
by 2030.
Number of diabetes sufferers
is expected to rise from the
current 415 million to 642
million by 2040.
By 2020, 50 % of global health
care expenditures – about $4
trillion – will be spent on
three leading causes of
death: ca rdiovascula r
diseases, cancer and respiratory
diseases.

4. THE SOLUTION
The AICube wants to provide cutting edge alternatives to ease prevention behaviors and deliver
predicting medicine solutions. The AICube suggests specific care treatments to improve life quality and
reduce the cost of healthcare consequently. TheAICube developed, designed, and patented DOC.D
(Data Organizing Collector Device), the first device that collects different biomarkers thanks to a non-
invasive daily routine.
DOC.D
Collect
Biomarkers on
daily bases
The AICube
Machine
Learning
Algorithm
The Cloud
Aggregate
information for
data-driven
decisions

5. ARTIFICIAL INTELLIGENCE
IMPLEMENTATION
BiomarkersValues Machine Learning
Electronic Health Records
Biomarkers Dataset
DNA mapping

6. TURNYOUR
BIOMARKERS’ DATA
INTO PREVENTION
The AICube network will constantly collects and
process customers' biomarker through a Machine
Learning algorithm to build up personalized
treatments, create life style guide lines, move patients
from care to prevention and develop new predictive
medicine.
Biosensors and Trackers
Move investment from Healthcare to Health
Prevention will increase life expectancy and will
reduce Healthcare cost
Artificial Intelligence
Healthcare is one of the largest and most rapidly
growing segments of AI.
Healthcare is poised to accelerate investments in AI
over the next three years.
Point of Prevention (PoP)
Non invasive daily data collection brings valuable
input to Machine Learning Algorithm.

7. OURVISION
Foundations built on an experienced team:
Business oriented attitude with proven results, high domains
knowledge in strategic areas
Leverage on Innovation:
Specific Machine Learning Algorithm integrated in AICube’s
Server
Reduce Healthcare cost through prevention
Noncommunicable diseases (NCDs), such as heart disease,
stroke, cancer, chronic respiratory diseases and diabetes, are
the leading cause of mortality in the world.

8. THETEAM
Board of Directors
• Stefano Russano - CEO & Founder
• Paolo Carmassi - Board Member
Fortune 100, FTSE 250 global business management.
Advisory Board (CSTS Healthcare members)
• Christos Klement
• Giannoula Klement
• Ali Hashemi
Operations and Innovation Management
• Matteo Giuffrida
Academic Fellow of the Department of Management and
Technology at Bocconi University
S. Russano P. Carmassi
C. Klement G. Klement A. Hashemi
M.Giuffrida

9. THETEAM
Communication & Marketing
• Fabio Meazzi
• Silva Castellani
Legal
• Alberto Randazzo
(Director of) Institutional Relations
• Anna Carmassi
Cybersecurity
• Sergio Dicandia
F. Meazzi S.Castellani
S. Dicandia A.RandazzoA.Carmassi

10. FINANCIAL
$15M
Revenue @ year 5
$8.2M
Profit after 5 years.
$6.5M
Ebit on year 5.
-4.000.000$
0$
4.000.000$
8.000.000$
12.000.000$
16.000.000$
Year 1 Year 2 Year 3 Year 4 Year 5
Revenue Gross Profit Expense Ebit

11. TRACTION
0 €
3.000.000 €
6.000.000 €
9.000.000 €
12.000.000 €
Year 1 Year 2 Year 3 Year 4 Year 5
Data DOC.D CUBE Cartridge
62% Sales of disposable
cartridge
Cost per test
53% Average GM on
Year 50.28$

12. THANKYOU